In the fight against cancer, timing is everything. The earlier a disease is detected, the better the chances of survival.
That’s the purpose behind screening clinical trial studies that test methods for catching diseases like mesothelioma at their earliest stages, often before symptoms begin.
There are several types of mesothelioma clinical trials, from treatment to prevention. Screening clinical trials can help identify high-risk individuals and prevent cancers from progressing unnoticed. For rare and aggressive diseases like mesothelioma, that can make a lifesaving difference.
What Are Screening Clinical Trials?
Screening clinical trials are research studies designed to evaluate new ways to detect diseases early, especially in people who don’t yet have symptoms but may be at higher risk. These trials test:
- New imaging techniques
- Blood-based or genetic screening tests
- Breath or urine tests for biomarkers
- Routine monitoring programs for high-risk populations
The goal is to determine whether a screening method can detect cancer earlier and more accurately than current practices without causing harm from false positives or unnecessary procedures.
Why Are Screening Trials Important?
Early detection improves treatment outcomes. In many cancers, identifying the disease in its early stages dramatically increases the likelihood of successful treatment.
Mesothelioma, for example, has much better survival rates in stage 1 and stage 2 compared to stage 3 and stage 4. The main reason is because aggressive surgery to remove most or all of the tumors is more likely to be successful in early stages.
Screening trials help determine:
- Whether a screening tool is safe, accurate and effective
- How well it reduces mortality or improves quality of life
- Which risk groups benefit most from early testing
- Whether a screening test leads to misdiagnosis or unnecessary follow-ups
For rare and aggressive cancers like mesothelioma, where late-stage diagnosis is the norm, effective screening could be a game-changer.
Mesothelioma and Screening Trials
Mesothelioma is caused by exposure to asbestos. The disease takes 20-50 years after exposure usually, which means people are almost never prepared or considering the possibility of developing this cancer.
Because it develops slowly over decades, there’s a unique opportunity to monitor high-risk groups (like veterans or industrial workers) before symptoms start. Could there be a way to screen for signs of asbestos in tissue linings where mesothelioma first develops? Could at-risk groups receive regular testing to detect the first tumors before they begin spreading?
Although mesothelioma is rare, researchers are exploring ways to screen people exposed to asbestos for early warning signs of disease.
Examples of Mesothelioma Screening Clinical Trials and Strategies
Low-Dose CT Scans for Asbestos-Exposed Workers
- What’s being tested: Scientists are testing the use of low-dose computed tomography (LDCT) to screen individuals with known asbestos exposure.
- Purpose: While LDCT is already used in lung cancer screening, researchers are exploring its use to catch early pleural changes in mesothelioma-prone individuals.
- Status: Not yet standard for mesothelioma, but ongoing studies aim to determine its usefulness in detecting early tumors or pleural thickening.
Biomarker Screening in Blood
- Goal: Identify elevated biomarker levels that signal the early development of mesothelioma, even before imaging shows tumors.
- Findings: While promising, no single biomarker has yet proven accurate enough for routine screening. Some research focuses on combining multiple markers to improve results.
Breath Analysis (VOC Screening)
- What’s being evaluated: Volatile organic compounds (VOCs) in exhaled breath that may be associated with mesothelioma
- Potential Benefit: A completely non-invasive way to screen large populations at risk
- Limitations: Still in early development; needs validation in larger studies
Australian Asbestos Screening Programs
- Australia has some of the highest mesothelioma rates in the world, and national programs like the Asbestos Diseases Research Institute have conducted screening studies on former miners and construction workers, integrating lung function tests, imaging, and biomarker research.
Who Can Join a Screening Clinical Trial?
- History of occupational asbestos exposure (e.g., construction, shipbuilding, military)
- Family history of working in at-risk occupations for asbestos exposure (potential secondhand asbestos exposure from bringing asbestos into the home)
- Age and general health factors
Final Thoughts: Screening Is a Window of Opportunity
Mesothelioma is an aggressive and rare cancer often diagnosed too late. That’s why screening clinical trials are essential. They offer a potential path to earlier diagnosis, better outcomes, and more effective monitoring in those most at risk.
While there’s no standard screening method for mesothelioma yet, ongoing trials continue to explore blood tests, imaging tools and even breath analysis to change that reality. If you have a history of asbestos exposure, staying informed about screening trials could offer access to promising new technologies and peace of mind. You can search for active trials at https://clinicaltrials.gov/.
Email registered nurse and mesothelioma patient advocate Karen Ritter at karen@mesotheliomaguide.com for help finding a clinical trial for mesothelioma.
Read More From Mesothelioma Guide’s Clinical Trials Blog Series
Here is a list of all published blogs in the series on mesothelioma clinical trials:
- Phase 1 clinical trials
- Phase 2 clinical trials
- Phase 3 clinical trials
- Phase 4 clinical trials
- Treatment clinical trials
- Diagnostic clinical trials
- Supportive care clinical trials
- Behavioral clinical trials
- Prevention clinical trials
Sources & Author
